Anzeige
Mehr »
Montag, 01.09.2025 - Börsentäglich über 12.000 News
Blockbuster-Potenzial und Übernahmefantasie: Hier entsteht das nächste Big Pharma-Ziel!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLTL | ISIN: US86150R1077 | Ticker-Symbol: 0GT
Tradegate
29.08.25 | 13:02
17,100 Euro
+1,18 % +0,200
1-Jahres-Chart
STOKE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
STOKE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,60017,10010:25
16,60017,10008:04

Aktuelle News zur STOKE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.08.Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress372- 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard...
► Artikel lesen
25.08.Stoke Therapeutics, Inc.: Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress305- 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard...
► Artikel lesen
18.08.Stoke Therapeutics stock price target lowered to $28 at BTIG on Zorevunersen data2
13.08.Where Stoke Therapeutics Stands With Analysts2
12.08.Stoke Therapeutics, Inc. - 10-Q, Quarterly Report2
12.08.Stoke Therapeutics GAAP EPS of -$0.40 beats by $0.13, revenue of $13.8M beats by $8.56M2
11.08.A Look Ahead: Stoke Therapeutics' Earnings Forecast1
11.08.Biogen Inc.: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome454- Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period - - Dravet syndrome is a rare genetic disease characterized by...
► Artikel lesen
STOKE THERAPEUTICS Aktie jetzt für 0€ handeln
11.08.Stoke Therapeutics, Inc. - 8-K, Current Report1
22.07.Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome23
18.07.Jefferies stuft Stoke Therapeutics mit "Buy" ein - Hohes Potenzial bei Epilepsie-Medikament11
18.07.Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential3
14.07.Stoke Therapeutics stock maintains Buy rating at H.C. Wainwright on positive study data2
10.07.Biogen Inc.: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress471- Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 - - These findings support...
► Artikel lesen
10.07.Stoke Therapeutics, Inc. - 8-K, Current Report1
09.07.Stoke Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
04.06.Stoke Therapeutics, Inc. - 8-K, Current Report2
15.05.Stoke Therapeutics stock target cut to $35 by H.C. Wainwright5
13.05.Stoke Therapeutics, Inc. - 10-Q, Quarterly Report1
13.05.Stoke Therapeutics GAAP EPS of $1.90, revenue of $158.57M4
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1